IRCT20150706023084N18
Completed
Phase 1
Investigating the effect of empagliflozin on patients with non alcoholic fatty liver diseases
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Diabetic patient with non alcoholic fatty liver.
- Sponsor
- Islamic Azad University
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diabetic patient
- •Fatty liver
- •Empagliflozin
Exclusion Criteria
- •Drug use for fatty liver
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
Phase 3
Evaluation of the effect of Empagliflozin on the severity of heart failure symptoms and echocardiography parameters in patients with congenital heart diseases with left-to-right shuntIRCT20120520009801N11Mashhad University of Medical Sciences44
Completed
Phase 3
Effect of Empagliflozin in prevention of kidney stone parametersIRCT20211203053261N2Hamedan University of Medical Sciences138
Not Yet Recruiting
Phase 3
Assessment of effectiveness of Empagliflozin in the management of Anemia in diabetes patientsCTRI/2024/02/063292SRM Insitute of Science and Technology
Recruiting
Phase 3
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90
Recruiting
Phase 2
Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after heart surgeryAtrial fibrillation after heart surgery.Paroxysmal atrial fibrillationIRCT20120520009801N9Mashhad University of Medical Sciences160